Section Arrow
AVLN.NASDAQ
- Avalyn Pharma Inc
Quotes are at least 15-min delayed:2026/05/05 01:18 EDT
Regular Hours
Last
 29.07
-0.77 (-2.58%)
Day High 
30.6683 
Prev. Close
29.84 
1-M High
30.2 
Volume 
357.30K 
Bid
27.5
Ask
29.9
Day Low
28.01 
Open
30.14 
1-M Low
26 
Market Cap 
-- 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High 30.2 
52-W Low 26 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.04/--
Enterprise Value
--
Balance Sheet
Book Value Per Share
-5.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LNAILunai Bioworks Inc.0.3246+0.0047+1.47%-- 
SGMOSangamo Therapeutics0.1776+0.0426+31.56%-- 
CNSPCNS Pharmaceuticals Inc7.84+5.5289+239.23%0PE
CABACabaletta Bio3.83+0.89+30.27%-- 
IOVAIovance Biotherapeutics3.85+0.45+13.24%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, whichare inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.